Nutritional compositions for modulating inflammation including exogenous vitamin k2

Abstract

Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.

1 . A method of modulating the effects of inflammation, the method comprising:
 administering to a patient in need of same a nutritional composition comprising effective amount of exogenous vitamin K2.   
     
     
         2 . The method of  claim 1  wherein the exogenous vitamin K2 is selected from the group consisting of MK-4, MK-7 and combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the exogenous vitamin K2 is MK-7. 
     
     
         4 . The method of  claim 1 , wherein the effective amount of exogenous vitamin K2 is from about 1 μs to about 100 μg. 
     
     
         5 . The method of  claim 1 , wherein the effective amount of exogenous vitamin K2 is from about 20 μg to about 90 μs. 
     
     
         6 . The method of  claim 1 , wherein the effective amount of exogenous vitamin K2 is from about 50 μg to about 80 μg. 
     
     
         7 . The method of  claim 1 , wherein the nutritional composition is in an administrable form selected from the group consisting of pharmaceutical formulations, nutritional formulations, tube-feed formulations, dietary supplements, functional foods and beverage products. 
     
     
         8 . The method of  claim 1 , the nutritional composition further comprising at least one component selected from the group consisting of prebiotic, probiotics, symbiotic, amino acid, protein, nucleotides, a fish oil, non-marine omega-3 fatty acid containing dietary fat source, phytonutrients, antioxidant, and combinations thereof. 
     
     
         9 . The nutritional composition of  claim 7 , wherein the amino acid is selected from the group consisting of proline, hydroxyproline, hydroxytyrosine, hydroxylysine and hydroxyserine and combinations thereof. 
     
     
         10 . The method of  claim 1 , wherein the modulation of the effects of inflammation is a reducing of the effects of inflammation. 
     
     
         11 . The method of  claim 1 , wherein the modulation of the effects of inflammation is a preventing of the effects of inflammation. 
     
     
         12 . The method of  claim 1 , wherein the modulation of the effects of inflammation is decreasing a rise of plasma TNF-α under conditions of inflammation. 
     
     
         13 . The method of  claim 1 , wherein the modulation of the effects of inflammation is blunting a drop in phosphorlyation for IKKα/β and NFκB p65 induction under conditions of inflammation. 
     
     
         14 . The method of  claim 1 , wherein the modulation of the effects of inflammation is abrogating a decrease in 4E-BP1(Thr-37) and ribosomal protein S6 phosphorylation under conditions of inflammation. 
     
     
         15 . The method of  claim 1 , wherein the modulation of the effects of inflammation is preserving the fractional rate of mixed muscle protein synthesis under conditions of inflammation. 
     
     
         16 . The method of  claim 1 , comprising the steps of:
 determining a patient's genetic predisposition to determine the likely efficacy of treatment with exogenous Vitamin K2; and   if determined to be efficacious, administering to a child in need of same a nutritional composition comprising an effective amount of exogenous vitamin K2 and a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.   
     
     
         17 . The method of  claim 16  wherein the genetic predisposition is determining the genotype. 
     
     
         18 . The method of  claim 16  wherein the genetic predisposition is used to determine the dosage of the exogenous Vitamin K2. 
     
     
         19 . The method of  claim 1 , wherein the patient is a child. 
     
     
         20 . The method of  claim 1 , wherein the patient has at least one condition selected from the group consisting of developmental delay, failure-to-thrive, inflammatory bowel disease, Crohn's disease, Crohn's Disease-associated osteopenia, Colitis, ulcerative colitis, celiac disease, gluten intolerance, neuromuscular dysfunction, cystic fibrosis, renal dysfunction, androgen deficiency, severe food allergy, short bowel syndrome, and combinations thereof.